The Food and Drug Administration (FDA) has granted 510(k) clearance to EarliPoint™ Evaluation to assist clinicians with the diagnosis and assessment of autism spectrum disorder (ASD) in children 16 to 30 months of age.
The EarliPoint Evaluation device utilizes eye-tracking technology to capture moment-by-moment looking behavior using a series of short video scenes displaying social interactions between children. The data are then compared to age-expected reference metrics to determine if the child is missing critical social information.
The EarliPoint Evaluation device utilizes eye-tracking technology to capture moment-by-moment looking behavior using a series of short video scenes displaying social interactions between children. The data are then compared to age-expected reference metrics to determine if the child is missing critical social information.
I don't have an anger problem, I have an idiot problem.